Cefepime
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Cefepime: From Bacterial Infections to Polyclonal Hyperviscosity Syndrome
One-Sentence Summary
Cefepime is a broad-spectrum cephalosporin antibiotic, originally used for streptococcal infection, bacterial pneumonia, and Pseudomonas aeruginosa and Staphylococcus aureus infections. The TxGNN model predicts it may be effective for polyclonal hyperviscosity syndrome, but there are 0 clinical trials and 0 publications supporting this prediction. It rests on a network-based model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Streptococcal infection, bacterial pneumonia, Pseudomonas aeruginosa infection, Staphylococcus aureus infection (the Singapore licence records contain no indication text) |
| Predicted New Indication | Polyclonal hyperviscosity syndrome |
| TxGNN Prediction Score | 98.69% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 4 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Cefepime is a beta-lactam (fourth-generation cephalosporin) antibacterial. Its efficacy against bacterial infections is established, but it has no known effect on serum viscosity or on the raised polyclonal immunoglobulins that characterise this syndrome.
The only conceivable link is indirect: treating infections in patients who have the condition. The high TxGNN score reflects a network-based pattern, not a supporting mechanism. This prediction should be treated as a weak hypothesis.
Other predictions for this drug were also reviewed. Two have mechanistic or preclinical plausibility and may deserve further study:
- Septicemic plague (score 97.32%): Yersinia pestis is a Gram-negative bacterium, so an antibacterial rationale is plausible. The only evidence is one preclinical mouse study (2007), with no human data.
- Infectious otitis media (score 95.02%): cefepime covers Pseudomonas aeruginosa and Staphylococcus aureus, common pathogens in chronic suppurative otitis media. The evidence is limited to case reports and a surveillance study.
Clinical Trial Evidence
Currently no related clinical trials registered for polyclonal hyperviscosity syndrome.
Literature Evidence
Currently no related literature available for polyclonal hyperviscosity syndrome.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN14658P | Cefepime-AFT Powder for Injection 1g/vial | Lyophilised powder for injection | Not stated in the compiled records |
| SIN14156P | Cefevon powder for solution for injection 2g/vial | Powder for injection | Not stated in the compiled records |
| SIN14988P | Cefepime Kabi powder for solution for injection or infusion 2g/vial | Powder for injection | Not stated in the compiled records |
| SIN14987P | Cefepime Kabi powder for solution for injection or infusion 1g/vial | Powder for injection | Not stated in the compiled records |
Safety Considerations
- Contraindications flagged in the knowledge graph (these come from network relationships, not label text): epilepsy, blood coagulation disease, Clostridium difficile colitis, colitis, perinatal necrotizing enterocolitis, impaired renal function, brain disease, and several myoclonic or movement disorders (for example familial myoclonic epilepsy, Unverricht-Lundborg syndrome, early myoclonic encephalopathy, opsoclonus-myoclonus syndrome, blepharospasm, focal hand dystonia).
- Neurotoxicity and renal considerations: cefepime is associated with dose-dependent neurotoxicity (encephalopathy), especially in renal impairment, and a published case report describes cefepime-induced acute interstitial nephritis.
- Drug Interactions: 100 interactions were identified. Moderate-level ones include the aminoglycosides kanamycin, neomycin and streptomycin, and picosulfuric acid. Others, such as amphotericin B, mannitol, morphine and metformin, are of unknown severity.
Please refer to the package insert for full safety information, as the label warnings were not available for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has only a model score behind it. There are no clinical trials or literature, and no plausible mechanism linking an antibacterial to polyclonal hyperviscosity syndrome. Cefepime's neurotoxicity and renal risks add caution.
To proceed, the following is needed:
- Mechanism of action data and any biological rationale for an effect on serum viscosity or immunoglobulin levels
- Package insert warnings and contraindications from the Singapore regulator (HSA)
- Approved indication text for the Singapore licences
- Consideration of better-supported candidates (septicemic plague, infectious otitis media) as research questions, starting with controlled human data
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.